Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.668,98
0,28%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ InflaRx NV (IFRX) InflaRx NV (IFRX) Notizie

IFRX

InflaRx NV (IFRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IFRX
DataOraFonteTitoloSimboloCompagnia
21/05/202422:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
21/05/202420:30GlobeNewswire Inc.InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsNASDAQ:IFRXInflaRx NV
08/05/202413:30GlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
30/04/202413:30GlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
24/04/202413:30GlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
21/03/202412:00GlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
19/03/202412:30GlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
22/02/202413:30GlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
25/01/202413:30GlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
04/01/202413:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
06/11/202313:30GlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
01/11/202312:30GlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
11/09/202313:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
30/08/202313:30GlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
10/08/202313:30GlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
12/07/202322:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
12/07/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
30/06/202322:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
28/06/202314:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
28/06/202313:30GlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
21/06/202313:00GlobeNewswire Inc.InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
11/05/202313:30GlobeNewswire Inc.InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
24/04/202322:48Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:IFRXInflaRx NV
18/04/202322:01GlobeNewswire Inc.InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionNASDAQ:IFRXInflaRx NV
14/04/202322:01GlobeNewswire Inc.InflaRx Announces Closing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
13/04/202314:48Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:IFRXInflaRx NV
12/04/202303:08GlobeNewswire Inc.InflaRx Announces Pricing of $40 Million Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
11/04/202322:00GlobeNewswire Inc.InflaRx Announces Public Offering of Ordinary SharesNASDAQ:IFRXInflaRx NV
05/04/202317:30Dow Jones NewsInflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19NASDAQ:IFRXInflaRx NV
04/04/202321:42Dow Jones NewsInflaRx's Gohibic Gets Emergency Use Authorization from FDA for Covid-19 Hospitalized PatientsNASDAQ:IFRXInflaRx NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IFRX

La tua Cronologia

BITMOT
782402
Netherlands Tf 4% Ge37 Eur
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network